サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1654646

CAR-T細胞療法の世界市場：2025年～2033年

Global CAR-T Cell Therapy Market - 2025-2033

出版日
ページ情報
英文 169 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
CAR-T細胞療法の世界市場：2025年～2033年
出版日: 2025年02月13日
発行: DataM Intelligence
ページ情報: 英文 169 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

CAR-T細胞療法の世界市場は、2024年に48億米ドルに達し、2033年までには204億米ドルに達すると予測され、予測期間中の2025年から2033年にはCAGR16.3％で成長する見込みです。

CAR-T細胞療法またはキメラ抗原受容体T細胞療法は、主にがん治療に用いられる先進的な免疫療法の一種です。この治療法では、免疫細胞の一種である患者自身のT細胞をキメラ抗原受容体（CAR）を発現するように改変することで、これらの細胞が特定のがん細胞を認識して攻撃できるようにします。CAR-T細胞療法は、急性リンパ芽球性白血病（ALL）やある種のリンパ腫など、特定の血液がんに対して特に有効です。しかし、CAR-T細胞の有効性を制限する可能性のある、より抑制的な腫瘍微小環境など、異なる課題を持つ固形がんにこのアプローチを適応させるための研究が進行中です。

CAR-T細胞療法の需要は、進行した血液がんを治療する可能性と、個別化された治療結果をもたらす能力によって、急速に伸びています。例えば、米国血液学会によると、研究参加者の71％がリンパ腫、28％が骨髄腫、1％がB細胞性急性リンパ芽球性白血病と診断されています。CAR-T治療の対象となった患者には、チサゲンレクロイセル（34％）、リソカブタジェンマラレクロイセル（16％）、アキシカブタジェンシロロイセル（13％）、イデカブタジェンビクロイセル（12％）が投与されました。全体として、患者の76％が寛解を達成し、33％がCAR-T療法の一般的な副作用である免疫エフェクター細胞関連神経毒性症候群を経験しました。

市場力学：

促進要因と抑制要因

血液がんにおける高い有効性

血液がんにおけるCAR-T細胞療法の高い有効性が市場を大きく牽引しており、予測期間中もCAR-T細胞療法市場を牽引すると予想されます。血液がん、特に従来の治療法に反応しなかった患者に対するCAR-T細胞療法の顕著な有効性により、CAR-T細胞療法の需要を増加させる血液がんの負担が増加しています。CAR-T療法は、急性リンパ芽球性白血病（ALL）、各種リンパ腫、多発性骨髄腫などの血液がんにおいて、高い奏効率と持続性を示しています。

例えば、米国血液学会によると、世界全体の血液学的悪性腫瘍の総患者数は、2030年までに約463万4,937人に達すると予測されています。2030年までに予測される血液学的悪性腫瘍の総患者数は、SDIのレベル別に以下の通りです：高SDI地域では111万3,313例、高中SDI地域では100万4,403例、低SDI地域では47万5,496例、低中SDI地域では79万5,475例、中SDI地域では124万4,424例です。

さらに、GileadのYescarta（axicabtagene ciloleucel）は、大細胞型B細胞リンパ腫（LBCL）患者において52％の完全寛解率を示しており、従来の化学療法後に再発した患者に重要な選択肢を提供しています。Bristol Myers SquibbのBreyanzi（lisocabtagene maraleucel）も同様の結果を示しており、LBCLにおける全奏効率は約73％でした。このように、CAR-T細胞療法の高い有効性がCAR-T細胞療法市場の成長を大きく後押ししています。

高い治療費

CAR-T細胞療法の高価格は、患者やヘルスケアシステムにとってのアクセシビリティとアフォーダビリティを制限することにより、CAR-T細胞療法市場の成長を著しく阻害します。特に包括的な償還の枠組みがない国々では、コストの障壁が患者のアクセスを制限し、治療法の市場浸透を制限しています。多くの地域では、長期的な費用対効果のデータがないため、ヘルスケアプロバイダーや保険会社がCAR-T細胞療法の保険適用を躊躇しており、臨床的有効性にもかかわらずその導入が制限されています。

例えば、米国国立衛生研究所によれば、CAR-T細胞療法の取得費用は、余分な処置や施設費用を除くと、1回の注入につき37万3,000ドルから47万5,000ドルです。さらに、CAR-T細胞療法は、改変T細胞の注入とそれに伴う病状のモニタリングが必要なため、通常は入院環境で実施され、7万9,466米ドルから8万5,267米ドルの追加費用がかかります。米国では、CAR-T細胞療法の点滴は約40万米ドルかかります。

目次

第1章 市場イントロダクションと範囲

  • 報告書の目的
  • 調査範囲と定義
  • 調査範囲

第2章 エグゼクティブの洞察と重要なポイント

  • 市場のハイライトと戦略的ポイント
  • 主な動向と将来の予測
  • スニペット：治療タイプ別
  • スニペット：薬剤タイプ別
  • スニペット：ターゲット抗原別
  • スニペット：用途別
  • スニペット：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 血液がんに対する高い有効性
      • 血液学以外の分野への応用拡大
    • 抑制要因
      • 高額な治療費
    • 機会
    • 影響分析

第4章 戦略的洞察と業界展望

  • 市場のリーダーと先駆者
    • 新たな先駆者と著名なプレーヤー
    • 最大の売上を誇るブランドを確立したリーダー
    • 確立された製品を持つ市場リーダー
  • 新興スタートアップ企業と主要イノベーター
  • CXOの視点
  • 最新の開発とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大のための推奨戦略
  • シナリオ分析ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格市場力学

第5章 CAR-T細胞療法市場、治療タイプ別

  • 自家CAR-T細胞療法
  • 同種異系CAR-T細胞療法

第6章 CAR-T細胞療法市場、薬剤タイプ別

  • アベクマ
  • ブレヤンジ
  • カルヴィクティ
  • テカルトゥス
  • キムリア
  • イエスカルタ

第7章 CAR-T細胞療法市場、ターゲット抗原別

  • CD19
  • BCMA（B細胞成熟抗原）
  • CD20
  • CD22
  • CD30
  • CD33
  • GD2
  • HER2
  • その他

第8章 CAR-T細胞療法市場、用途別

  • 急性リンパ性白血病（ALL）
  • 非ホジキンリンパ腫
  • 慢性リンパ性白血病（CLL）
  • 多発性骨髄腫（MM）
  • 濾胞性リンパ腫
  • その他

第9章 CAR-T細胞療法市場、地域別市場分析と成長機会

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州地域
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢と市場ポジショニング

  • 競合概要と主要な市場企業
  • 市場シェア分析とポジショニングマトリックス
  • 戦略的パートナーシップ、合併、買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第11章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
    • SWOT分析
  • Gilead Sciences, Inc.
  • Bristol Myers Squibb company
  • Johnson & Johnson
  • Autolus Therapeutics
  • Pfizer Inc.
  • BioNTech SE.
  • Merck KGaA
  • Allogene Therapeutics
  • Atara Biotherapeutics, Inc.

第12章 前提条件と調査手法

  • データ収集方法
  • データの三角測量
  • 予測技術
  • データの検証と検証

第13章 付録

目次
Product Code: BT1147

The global CAR-T cell therapy market reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR-T cell therapy or Chimeric Antigen Receptor T-cell therapy, is an advanced type of immunotherapy used primarily in cancer treatment. It involves engineering a patient's own T cells, a type of immune cell by modifying them to express a chimeric antigen receptor (CAR) that allows these cells to recognize and attack specific cancer cells. CAR-T cell therapy has been particularly effective for certain blood cancers, such as acute lymphoblastic leukemia (ALL) and certain types of lymphoma. However, research is ongoing to adapt this approach for solid tumors, which have different challenges, like a more suppressive tumor microenvironment that can limit CAR-T cell effectiveness.

The demand for CAR-T cell therapy is growing rapidly, driven by its potential to treat advanced blood cancers and its ability to deliver personalized treatment outcomes. For instance, according to the American Society of Hematology, 71% of the participants in the research received a lymphoma diagnosis, 28% myeloma and 1% B-cell acute lymphoblastic leukemia. Most frequently, tisagenlecleucel (34%), lisocabtagene maraleucel (16%), axicabtagene ciloleucel (13%) and idecabtaene vicleucel (12%) were given to patients who qualified for CAR-T treatment. Overall, 76% of patients achieved remission and 33% experienced immune effector cell-associated neurotoxicity syndrome, a common side effect of CAR-T therapy.

Market Dynamics: Drivers & Restraints

High efficacy in hematological cancers

The high efficacy of CAR-T cell therapy in hematological cancers is significantly driving the market and is expected to drive the CAR-T cell therapy market over the forecast period. There is an increasing burden of hematological cancers which increases the demand for CAR-T cell therapy due to its remarkable efficacy in treating hematological cancers, especially in patients who have not responded to conventional therapies. CAR-T therapies have demonstrated high response rates and durability in blood cancers like acute lymphoblastic leukemia (ALL), various forms of lymphoma and multiple myeloma.

For instance, according to the American Society of Hematology, globally, the total number of hematological malignancy cases is projected to reach approximately 4,634,937 by 2030. The projected total number of hematological malignancy cases by 2030 across different levels of SDI are as follows: 1,113,313 cases in high-SDI areas, 1,004,403 cases in high-middle SDI areas, 475,496 cases in low-SDI areas, 795,475 cases in low-middle SDI areas, and 1,244,424 cases in middle-SDI areas.

Additionally, Gilead's Yescarta (axicabtagene ciloleucel) has shown a 52% complete remission rate in large B-cell lymphoma (LBCL) patients, offering a significant alternative for those who have relapsed after conventional chemotherapy. Breyanzi (lisocabtagene maraleucel) from Bristol Myers Squibb has demonstrated similar results, with overall response rates around 73% in LBCL. Thus, the high efficacy of CAR-T cell therapy significantly drives CAR-T cell therapy market growth.

High cost of therapy

The high cost of CAR-T cell therapy significantly hampers its market growth by limiting accessibility and affordability for patients and healthcare systems. The cost barrier restricts patient access, especially in countries without comprehensive reimbursement frameworks and limits the therapy's market penetration. In many regions, healthcare providers and insurers hesitate to cover CAR-T cell therapy due to the lack of long-term cost-benefit data, thus constraining its adoption despite clinical efficacy.

For instance, according to the National Institute of Health, the acquisition cost of CAR T-cell therapy is between $373,000 to $475,000 per infusion, excluding extra procedures and facility costs. Moreover, the therapies are usually performed in an inpatient environment since they require the infusion of modified T cells and consequent monitoring of the disease status, costing an additional $79,466 to $85,267. In the United States, an infusion of CAR T-cell therapy costs about $400,000.

Segment Analysis

The global CAR-T cell therapy market is segmented based on therapy type, drug type, target antigen, application and region.

Therapy Type:

The allogeneic CAR-T cell therapy segment is expected to dominate the global CAR-T cell therapy market share

The allogeneic CAR-T cell therapy segment holds a major portion of the CAR-T cell therapy market share and is expected to continue to hold a significant portion of the CAR-T cell therapy market share over the forecast period due to its potential to overcome the limitations of autologous (patient-specific) CAR-T cell treatments. Unlike autologous CAR-T, which requires extracting and modifying a patient's own T cells, allogeneic CAR-T uses "off-the-shelf" T cells from healthy donors.

For instance, according to a study conducted by the National Institute of Health (NIH), patients treated with allogeneic CAR-T cells had higher remission rates, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies.

Since autologous CAR-T therapies require a personalized manufacturing process that takes several weeks, they aren't ideal for patients with aggressive cancers needing urgent intervention. Allogeneic CAR-T therapies offer pre-manufactured, readily available options, shortening the time from diagnosis to treatment. This immediacy benefits patients with rapidly progressing cancers who cannot wait for cell manufacturing.

Application:

The multiple myeloma segment is expected to dominate the global CAR-T cell therapy market share

The multiple myeloma segment holds a major portion of the CAR-T cell therapy market share and is expected to continue to hold a significant portion of the market share over the forecast period. CAR-T cell therapy is increasingly used for treating multiple myeloma, especially for patients with relapsed or refractory cases. Multiple myeloma, a cancer of plasma cells, has shown responsiveness to CAR-T treatments targeting specific antigens found on cancer cells.

The success of BCMA-targeted CAR-T therapies is driving research and development in multiple myeloma, encouraging companies to invest in further CAR-T innovations for this condition. For instance, in October 2024, Aurigene Oncology Limited released the Phase 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study - India's first trial for a novel autologous BCMA-directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma.

The expanding FDA approvals for CAR-T in multiple myeloma treatment highlight its growing importance in this cancer type, with increasing patient access as more CAR-T products become available. For instance, in April 2024, the U.S. Food and Drug Administration (FDA) approved the CAR T-cell therapies ciltacabtagene autoleucel (cilta-cel; Carvykti) and idecabtagene vicleucel (ide-cel; Abecma) for earlier treatment of adults with multiple myeloma. Before these approvals, patients had to receive at least four lines of treatment before they were eligible for CAR T-cell therapy.

The non-Hodgkin lymphoma segment is the fastest-growing segment in the CAR-T cell therapy market

The non-Hodgkin lymphoma segment is expected to be the fastest-growing segment in the CAR-T cell therapy market over the forecast period. CAR-T cell therapy is showing strong promise for treating non-Hodgkin lymphoma, a type of blood cancer that often becomes resistant to traditional treatments like chemotherapy and radiation. This therapy targets specific proteins in lymphoma cells, allowing for a focused and effective attack by the patient's immune cells.

For instance, in May 2024, Bristol Myers Squibb cleared the U.S. Food and Drug Administration (FDA) approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. This FDA approval marks the fourth distinct subtype of non-Hodgkin lymphoma for which Breyanzi is approved, making it the CAR-T cell therapy available to treat the broadest array of B-cell malignancies.

Geographical Analysis

North America is expected to hold a significant position in the global CAR-T cell therapy market

North America region is expected to hold the largest share in CAR-T cell therapy market over the forecast period. According to the Leukemia & Lymphoma Society, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. An estimated combined total of 187,740 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2024. New cases of leukemia, lymphoma and myeloma are expected to account for 9.4 percent of the estimated 2,001,140 new cancer cases that will be diagnosed in the US in 2024. This rising prevalence of hematological cancers is boosting the demand for CAR-T cell therapy in the region, especially in the United States.

North America, particularly the United States is home to many of the world's leading biotech and pharmaceutical companies that are at the forefront of CAR-T cell therapy research. Major players such as Gilead Sciences, Novartis and Bristol Myers Squibb have established significant R&D facilities in the region, focusing on developing and refining CAR-T cell therapies.

For instance, in March 2024, Bristol Myers Squibb released that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Asia Pacific is growing at the fastest pace in the CAR-T cell therapy market

The Asia Pacific region is experiencing the fastest growth in the CAR-T cell therapy market. Hematological cancer rates are rising sharply in the APAC region, particularly blood cancers such as leukemia, lymphoma, and multiple myeloma, which are treatable with CAR-T therapies.

For instance, countries like China and India are seeing an increase in the incidence of hematologic cancers due to changing lifestyles, aging populations, and increased awareness. According to Shalby Hospitals, Inc., for every 5 minutes, someone in India is diagnosed with blood cancer, and an estimated 70,000 people die every year because of blood cancer, contributing to an increasing demand for innovative therapies like CAR-T cell therapy.

The regulatory environment in APAC is evolving rapidly, allowing faster approval and adoption of CAR-T therapies. China's National Medical Products Administration (NMPA) approved the first domestic CAR-T therapy, Kymriah (tisagenlecleucel), in 2019 for B-cell acute lymphoblastic leukemia (ALL) and later expanded approval to lymphoma treatments. Other countries in the region, such as Japan and South Korea, are following similar paths to introduce CAR-T therapies into their healthcare systems, making the market more accessible

Competitive Landscape

The major global players in the CAR-T cell therapy market include Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Autolus Therapeutics, Pfizer Inc., BioNTech SE., Merck KGaA, Allogene Therapeutics, Atara Biotherapeutics, Inc. and among others.

Emerging Players

The emerging players in the CAR-T cell therapy market include AstraZeneca, Eli Lilly and Company, JW Therapeutics, and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global CAR-T cell therapy market report delivers a detailed analysis with 70 key tables, more than 73 visually impactful figures, and 169 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Therapy Type
  • 2.4. Snippet by Drug Type
  • 2.5. Snippet by Target Antigen
  • 2.6. Snippet by Application
  • 2.7. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. High Efficacy in Hematological Cancers
      • 3.1.1.2. Expanding Applications Beyond Hematology
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Therapy
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. CAR-T Cell Therapy Market, By Therapy Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 5.1.2. Market Attractiveness Index, By Therapy Type
  • 5.2. Autologous CAR-T Cell Therapy *
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Allogeneic CAR-T Cell Therapy

6. CAR-T Cell Therapy Market, By Drug Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 6.1.2. Market Attractiveness Index, By Drug Type
  • 6.2. Abecma*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Breyanzi
  • 6.4. Carvykti
  • 6.5. Tecartus
  • 6.6. Kymriah
  • 6.7. Yescarta

7. CAR-T Cell Therapy Market, By Target Antigen

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 7.1.2. Market Attractiveness Index, By Target Antigen
  • 7.2. CD19*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. BCMA (B-cell maturation antigen)
  • 7.4. CD20
  • 7.5. CD22
  • 7.6. CD30
  • 7.7. CD33
  • 7.8. GD2
  • 7.9. HER2
  • 7.10. Others

8. CAR-T Cell Therapy Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Acute Lymphoblastic Leukemia (ALL)*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Hodgkin Lymphoma
  • 8.4. Chronic Lymphocytic Leukemia (CLL)
  • 8.5. Multiple Myeloma (MM)
  • 8.6. Follicular Lymphoma
  • 8.7. Others

9. CAR-T Cell Therapy Market, By Regional Market Analysis and Growth Opportunities

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.7.1. U.S.
      • 9.2.7.2. Canada
      • 9.2.7.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.7.1. Germany
      • 9.3.7.2. U.K.
      • 9.3.7.3. France
      • 9.3.7.4. Spain
      • 9.3.7.5. Italy
      • 9.3.7.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.7.1. Brazil
      • 9.4.7.2. Argentina
      • 9.4.7.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.7.1. China
      • 9.5.7.2. India
      • 9.5.7.3. Japan
      • 9.5.7.4. South Korea
      • 9.5.7.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target Antigen
    • 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

  • 10.1. Competitive Overview and Key Market Players
  • 10.2. Market Share Analysis and Positioning Matrix
  • 10.3. Strategic Partnerships, Mergers & Acquisitions
  • 10.4. Key Developments in Product Portfolios and Innovations
  • 10.5. Company Benchmarking

11. Company Profiles

  • 11.1. Novartis AG*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
    • 11.1.5. SWOT Analysis
  • 11.2. Gilead Sciences, Inc.
  • 11.3. Bristol Myers Squibb company
  • 11.4. Johnson & Johnson
  • 11.5. Autolus Therapeutics
  • 11.6. Pfizer Inc.
  • 11.7. BioNTech SE.
  • 11.8. Merck KGaA
  • 11.9. Allogene Therapeutics
  • 11.10. Atara Biotherapeutics, Inc.

LIST NOT EXHAUSTIVE

12. Assumption and Research Methodology

  • 12.1. Data Collection Methods
  • 12.2. Data Triangulation
  • 12.3. Forecasting Techniques
  • 12.4. Data Verification and Validation

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us